TaxolCur, LLC (“TaxolCur” or the “Company”) is a bio-pharmaceutical company based in West Berlin, NJ that is focused on the treatment of canine cancer.
TaxolCur has developed a unique drug combination effective against canine cancers with a focus on the following:
- Melanoma (MM) Our initial indication
- Hemangiosarcoma (HSA) Secondary indication
- Osteosarcoma (OSCA) Secondary indication
TaxolCur™ is a patented drug that kills cancer cells in 72 hours in vitro and has proven efficacious in laboratory animal cancer studies without side effects (studies available).
TaxolCur™ has been tested in 2 cases of canine melanoma with dramatic efficacy on a “compassionate” use basis.
TaxolCur is working with the Center for Veterinary Medicine (CVM) of the FDA toward approval for its drugs through the MUMS (Minor Use in Major Species) program for animal applications, which is modeled on the FDA’s Orphan Drug program for humans.
- Lower cost and rapid market entry (2 years)
- 7-year market exclusivity
TaxolCur expects to be a leader in the canine cancer market.
